Cargando…
KRAS mutation: from undruggable to druggable in cancer
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of KRAS is c...
Autores principales: | Huang, Lamei, Guo, Zhixing, Wang, Fang, Fu, Liwu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591115/ https://www.ncbi.nlm.nih.gov/pubmed/34776511 http://dx.doi.org/10.1038/s41392-021-00780-4 |
Ejemplares similares
-
Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019) -
Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022) -
Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
por: Lu, Bin, et al.
Publicado: (2021) -
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
por: Lam, Kuen Kuen, et al.
Publicado: (2023) -
KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
por: El Osta, Badi
Publicado: (2023)